Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus <scp>dipeptidyl peptidase‐4</scp> inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data-Reference-Cited by-同舟云学术

Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data

Published:2023-06-29 Issue:10 Volume:25 Page:3054-3058
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Schechter Meir¹²³^ORCID,Melzer Cohen Cheli⁴^ORCID,Zelter Tamir¹²,Yanuv Ilan¹²,Rozenberg Aliza¹²,Chodick Gabriel⁴⁵,Karasik Avraham⁴⁶,Mosenzon Ofri¹²^ORCID

Affiliation:

1. Diabetes Unit, Department of Endocrinology and Metabolism Hadassah Medical Center Jerusalem Israel

2. Faculty of Medicine Hebrew University of Jerusalem Jerusalem Israel

3. Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen, University of Groningen Groningen The Netherlands

4. Maccabi Institute for Research and Innovation Maccabi Healthcare Services Tel‐Aviv Israel

5. School of Public Health Sackler, Faculty of Medicine Tel Aviv University Tel Aviv Israel

6. Tel Aviv University Tel Aviv Israel

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference19 articles.

1. Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Barriers to early diagnosis of chronic kidney disease and use of sodium‐glucose cotransporter‐2 inhibitors for renal protection: A comprehensive review and call to action;Diabetes, Obesity and Metabolism;2024-08-14